SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community grapples with mixed sentiments amidst ongoing price stagnation, despite some believing a potential merger involving Zero Hash and Mastercard, alongside progress on the Clarity Act, could be catalysts. Many holders are expressing frustration over consistent declines, while others are actively accumulating, pointing to Flexa's real-world utility with major merchants and recent patents as reasons for long-term optimism. The debate rages between those who see it as a foundational payment collateral token and those who fear it's a 'dead project' that continually disappoints.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing highly polarized sentiment, with many in the community expressing frustration over significant losses and year-end tax-loss selling contributing to downward pressure. Despite widespread discussions questioning its utility and sustained underperformance relative to other major cryptocurrencies, a dedicated segment of holders maintains long-term conviction, eagerly anticipating a future resurgence.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending with a massive volume surge and price rally following news of a strategic manufacturing partnership aimed at scaling production of its drug screening reader for future U.S. market entry. The community is intensely divided, with bulls pointing to the low float and the positive impact of a $10 million private placement on its balance sheet, while bears express significant concern over dilution, the company's reverse split history, and the offering's terms.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to massive trading volume and a significant price surge, sparking intense community discussion around its low-float SPAC nature. Traders are actively anticipating further upward movement and a potential squeeze, drawing parallels to other recently explosive micro-cap plays that have experienced rapid ascents.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is generating significant buzz as a low-float SPAC, with traders actively discussing its potential for a substantial price run. The community is drawing strong parallels to recent 'shell company rippers' like ESHA, anticipating a considerable upward movement fueled by limited circulating shares and growing speculative interest.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending due to its new integration with a Stripe-owned fiat anchor, which enables seamless, compliant bank-to-stablecoin transfers at a verified 11 million transactions per second. The community sees it as a potentially undervalued Layer 1 blockchain, poised to become essential financial infrastructure for institutions by offering high-speed, regulated settlement rails. This focus on enterprise-grade plumbing for global finance differentiates it from many other crypto projects.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing significant upward momentum as the FDA granted Priority Review for its AXS-05 in Alzheimer's disease agitation, with a PDUFA target date of April 30, and confirmed a clear path for its AXS-12 narcolepsy treatment. This major regulatory progress, alongside robust Auvelity sales growth and numerous analyst price target increases, has ignited strong bullish sentiment across the community. Many are celebrating long-term holdings and are optimistic about Axsome's potential to capitalize on substantial market opportunities in CNS disorders.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending with significant community anticipation for the start of a new yearly cycle, driving strong bullish sentiment for substantial long-term gains. Many investors are actively accumulating, citing historical patterns that suggest an imminent upward trajectory. The discussion is marked by strong convictions from bulls, despite ongoing skepticism from bears regarding its immediate outlook.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is trending amid intense community debate, primarily driven by widespread shareholder frustration with CEO Richard Paulson and the board, whom many accuse of continuous value destruction and mismanagement. Recent financing and a reverse stock split, while extending the cash runway, have amplified concerns about dilution and executive accountability. Despite this pervasive negative sentiment toward leadership, significant bullish options activity and anticipation for upcoming Phase 3 trial readouts in Myelofibrosis and Endometrial Cancer highlight an underlying belief in the company's scientific potential, contingent on a change in management.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics (CVKD) is trending due to recent strategic moves, including pipeline expansion through acquisitions and manufacturing advancements for its lead anticoagulant candidate, Tecarfarin. The market is weighing the potential of these developments, including analyst-assigned price targets and FDA designations, against community concerns about cash burn, dilution, and the company's ability to fund pivotal Phase 3 trials. This creates a polarized discussion, highlighting the high-stakes nature of micro-cap biopharma investments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

More Fed Rate Cuts in 2026? ETFs to Play the Opportunities

Softer inflation and dovish signals point to more 2026 rate cuts. These ETFs can help investors ride potential gains.

<ul class="summary-bullets"><li>The company projects FY26 adjusted EPS in the range of €1.90 to €2.05.</li><li>It estimates FY26 revenue in the range of €2.30 billion to €2.35 billion.</li><li>Birkenstock cited headwinds from currency translation and incremental tariffs on its projections.</li></ul>Birkenstock Holding (<a href="https://stocktwits.com/symbol/BIRK">BIRK</a>) shares tumbled nearly 12% in Thursday’s premarket after the company’s FY26 revenue and adjusted profit projections fell below analyst estimates, as tariff uncertainty weighs on demand. &nbsp;&nbsp;The company that largely makes its products in Germany has increased prices to mitigate the impact of Donald Trump’s 15% tariffs on EU imports, but continues to see muted sales growth as it joins a slew of consumer companies hurt by sweeping U.S. tariffs and elevated inflation.&nbsp;The German footwear company projected adjusted profit for FY26 in the range of €1.90 to €2.05 per share ($2.23 to $2.40), below analyst estimates of €2.09 per share, according to Fiscal.ai. It also projected a 100-basis-point hit to its annual gross margin due to the tariffs' impact.&nbsp;<h2 class="st-heading-2">Revenue Projections</h2>The company’s FY26 revenue estimate of €2.30 billion to €2.35 billion also fell below the €2.39 billion estimate. However, the company’s fourth quarter (Q4) revenue of €526 million edged above analyst estimates of €521 million, as tariff impact was somewhat cushioned by robust demand for its products.&nbsp;The company said it expects to invest in capital expenditures of €110 million to €130 million in 2026, well above the €85 million it invested in 2025 to expand production capacity.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around BIRK remained ‘extremely bullish’, and message volume remained ‘extremely high’. The stock was among the top 10 trending stocks on Stocktwits.<figure class="image"><img style="aspect-ratio:643/72;" src="https://news.stocktwits-cdn.com/Capture_1_PNG_a8c4c99ec1.webp" alt="On Stocktwits, the retail sentiment around BIRK remained ‘extremely bullish’, and message volume remained ‘extremely high’. " width="643" height="72"></figure>Shares in Birkenstock have fallen 19% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: €1 = $1.17) &nbsp;

Various Birkenstock shoes are displayed on shelves in a Birkenstock store on Ehrenstraße. Photo: Rolf Vennenbernd/dpa (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Birkenstock Stock Tumbles 12% Pre-Market After FY26 Projections Fail To Impress Investors

Birkenstock projected a muted sales growth for FY26, and its adjusted profit estimate came below analyst expectations, as U.S. tariffs continue to impact its business.  

Equity

Birkenstock projected a muted sales growth for FY26, and its adjusted profit estimate came below analyst expectations, as U.S. tariffs continue to impact its business.  


Is First Trust Consumer Discretionary AlphaDEX ETF (FXD) a Strong ETF Right Now?

Consumer Discretionary ETFs Set for a Comeback?

Should You Invest in the First Trust Consumer Discretionary AlphaDEX ETF (FXD)?

Kohl’s (KSS) shares jumped 13.5% at Thursday’s open following the release of first-quarter results that showed a significantly smaller loss than analysts had anticipated, and reaffirmed its full-year guidance.The department store chain reported a diluted loss per share of $0.13, narrower than the expected loss of $0.22, as per Koyfin data.&nbsp;Its revenue decreased 4.1% year-over-year (YoY) to $3.05 billion, missing Wall Street’s estimate of $3.06 billion by a whisker. Comparable sales were down 3.9% as compared to the previous year.&nbsp;“Our first quarter performance was ahead of our expectations, and the actions we are taking are starting to make progress with early signs of a positive impact,” said interim CEO Michael Bender, marking his quarterly earnings debut.Bender took over after Kohl’s fired former CEO Ashley Buchanan earlier this month, just four months into his tenure, for trying to steer business to his romantic partner, Chandra Holt. The company&nbsp;stated that Buchanan did not disclose the relationship as required by its ethics policy and deemed his actions&nbsp;to be cause for dismissal.During the first quarter (Q1), gross margin as a percentage of net sales rose by 37 basis points to 39.9%. Selling, general, and administrative (SG&amp;A) expenses declined 5.2% year-over-year to $1.2 billion, representing 36.0% of total revenue, a decrease of 32 basis points.Operating income increased to $60 million from $43 million in the prior year, equivalent to 1.9% of total revenue.&nbsp;The company reported a net loss of $15 million,&nbsp;an improvement from the $27 million net loss in the previous year. Inventory rose 2% YoY to $3.1 billion. Operating cash flow was negative $92 million.For the full year 2025, the company continues to expect net sales to decline between 5% and 7%, with comparable sales decreasing between 4% and 6%.&nbsp;Operating margin is projected to range from 2.2% to 2.6%, while diluted earnings per share are expected to fall between $0.10 and $0.60.&nbsp;Capital expenditures are forecasted to be between $400 million and $425 million.&nbsp;<a href="http://stocktwits.com/symbol/KSS">Kohl’s stock</a> has fallen 35% this year, and more than 65% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kopin-cfo-rich-sneider-to-retire-after-25-years/ch0AYq5RbtY">Kopin CFO Rich Sneider To Retire After 25 Years</a>

The Kohl'scorporate logo is displayed on a sign at their store on January 31, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Kohl’s Stock Jumps On Q1 Earnings Beat, Reaffirmed Guidance

 For the full year 2025, the company continues to expect net sales to decline between 5% and 7%, with comparable sales decreasing between 4% and 6%. 

Carter's Inc (CRI) shares declined over 11% on Friday after the&nbsp;kids'&nbsp;apparel retailer posted lower quarterly revenue and profit and suspended its 2025 business forecast.The company said its move is influenced by the recent leadership transition and "significant uncertainty surrounding proposed new tariffs and potential related impact on the business."Carter's appointed Douglas Palladini, a former senior executive for VF Corp's (VFC) Vans brand, as CEO on April 3.For the fiscal first quarter ending&nbsp;March 29, Carter's said revenue declined to $629.8 million from $661.5 million a year earlier. However, it exceeded the $623.8 million analyst estimate from FactSet.Adjusted earnings were $0.66 per share, down from $1.04 a year earlier, but exceeded the estimate of $0.53.The company's annual revenue has declined over the last three years, weighed down by persistent inflation and elevated interest rates, which, among other things, have reduced consumer spending among families with young children.Carter's is one of North America's largest clothing brands for babies and young children. It sells under labels such as OshKosh B'gosh and Skip Hop and offers exclusive lines for major retailers: Just One You and Precious Firsts (Target), Child of Mine (Walmart), and Simple Joys (Amazon).It also operates over 1,000 self-owned stores in the U.S. and Canada.On Stocktwits, retail sentiment for Carter's was in the 'neutral' territory, with 'high' message volume.<figure class="image"><img style="aspect-ratio:812/189;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_28_at_9_13_53_AM_png_bd9528e7db.webp" alt="Screenshot 2025-04-28 at 9.13.53 AM.png" width="812" height="189"><figcaption>CRI sentiment and message volume as of April 27 | Source: Stocktwits</figcaption></figure>A user posted saying that withdrawing the guidance was a smart move on the company's part.<stembedurl>https://stocktwits.com/Justinian/message/612705112</stembedurl><a href="https://stocktwits.com/symbol/CRI">Shares of the company</a> are down 37.5% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A woman hangs up baby clothes at a trade fair stand. (Photo by Christoph Reichwein/picture alliance via Getty Images)

Carter's Stock Dives On Guidance Suspension, Poor Q1 Print — Retail Traders Watch Cautiously

Retail investors are waiting for the new chief executive's moves following his appointment earlier this month to revive the struggling business.

Shares of closeout store Ollie’s Bargain Outlet rose 2% in after-hours trading Wednesday following the company’s fourth-quarter earnings, but retail sentiment was cautious.For Q4, Ollie’s missed revenue estimates but its EPS of $1.19 was in line with Wall Street analyst expectations. Its revenue stood at $667.08 million, below street expectations of $675.39 million.While comparable store sales increased 2.8% from the prior year, said the company.“With so many retailers closing stores or going bankrupt in the past year, there are a considerable number of abandoned customers, merchandise, real estate, and talent in the marketplace,” said CEO Eric van der Valk.“We think there is a unique opportunity to take on some of these assets in a manner that strengthens our competitive positioning, broadens our footprint, and bolsters shareholder returns for years to come.”Ollie’s announced a new share repurchase authorization for an additional $300 million of the company’s outstanding common stock.On the store expansion front, the company highlighted its purchase of an additional 40 former Big Lots store locations, paving the way to target store growth to 75 stores for fiscal 2025.The company noted that its gross margin increased 20 basis points to 40.7%, primarily driven by lower supply chain costs, and offset by a slightly lower merchandise margin.Sentiment on Stocktwits remained ‘neutral’ compared to a day ago. Message volume was ‘extremely high’<figure class="image"><img style="aspect-ratio:1308/322;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_20_at_1_08_40_PM_png_6259eb38f9.webp" alt="Screenshot 2025-03-20 at 1.08.40 PM.png" width="1308" height="322"><figcaption>Olli sentiment meter and message volume on March 19</figcaption></figure>Olli sentiment meter and message volume on March 19 as of 11 pm ETOllie’s Bargain Outlet stock is down 1.6% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ollie’s Bargain Outlet Stock Rises After Q4 Earnings, Share Buyback Program: Retail Remains Cautious

Shares of closeout store Ollie’s Bargain Outlet Holdings Inc. have fallen 6.9% in the past month, even as the retailer received a price target hike ahead of its fourth-quarter results, with retail sentiment upbeat.Ollie’s is set to report Q4 results before the market opens on Wednesday.Wall Street analysts expect the company to post a 30% increase in revenue to $674.5 million and a 106% rise in earnings per share to $1.19 for the fourth quarter, according to Koyfin. Ollie’s has beaten EPS estimates thrice in the past four quarters and revenue twice in the same period. It recently announced the acquisition of 40 former Big Lots store leases from Gordon Brothers, eventually leading to RBC Capital raising its price target to $133 from $130 and with an Outperform rating.The firm's model is largely unchanged outside of revising its unit and pre-opening expense estimates and is positive on the stock's risk-reward given its "strong" underlying fundamentals, said the report.Sentiment on Stocktwits ended on a ‘bullish’ note on Tuesday compared to ‘bearish’ a day ago. Message volume climbed to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1306/312;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_19_at_7_56_11_AM_png_584beeec94.webp" alt="Screenshot 2025-03-19 at 7.56.11 AM.png" width="1306" height="312"><figcaption>Olli sentiment meter and message volume on March 17 as of 9 pm ET</figcaption></figure> "Taking a gamble with $OLLI after the drop today. $110 calls," wrote one user.<stembedurl>https://stocktwits.com/sdsdsdsddww/message/608486285</stembedurl>In February, the company received a downgrade from Jefferies, which cut the rating to ‘Hold’ from ‘Buy’ with a price target of $111, reduced from $125, The Fly reported.According to the report, the brokerage warned about a storm brewing in the consumer discretionary sector as industry inventories are rising for the first time in two years.Ollie’s Bargain stock is down 9.7% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 An exterior view of an Ollie's Bargain Outlet store at the Orchard Hills Shopping Center. (Photo by Paul Weaver/SOPA Images/LightRocket via Getty Images)

Ollie’s Bargain Stock Falls Ahead Of Q4 Earnings, But Retail’s Bullish

Sentiment on Stocktwits ended on a ‘bullish’ note on Tuesday compared to ‘bearish’ a day ago. 

Shares of Kohl’s Corp. recovered slightly in after-hours trading on Tuesday after diving nearly 24% in the regular session following the retailer’s worse-than-expected 2025 guidance, but retail sentiment was upbeat.Kohl’s posted earnings per share (EPS) of $0.95 in the fourth quarter, surpassing estimates of $0.72.Its revenue stood at $5.18 billion, falling 9.4% year-over-year but in line with consensus estimates of $5.18 billion. Comparable sales declined 6.7% in the fourth quarter.Kohl CEO Ashley Buchanan said the retailer has identified key focus areas and is taking action in 2025 to reposition the company as part of a turnaround strategy. The company plans to bring curated, more balanced offerings to re-establish itself as a “leader in quality and value.”For 2025, Kohl’s projected net sales to decline between 5% and 7%, steeper than the consensus estimate of a 1.6% decrease. Comparable sales are expected to fall between 4% and 6% during the year.Diluted EPS is expected to range between $0.10 and $0.60."Kohl's is built on a strong foundation that includes operating more than 1,100 conveniently located stores nationwide, serving over 60 million customers, with 30 million of those customers being Kohl's Loyalty Members,” said Buchanan.Kohl's also reduced its quarterly cash dividend to $0.12 per share, &nbsp;payable on Apr. 2 to shareholders of record at the close of business on Mar. 21. The dividend has been reduced from $0.50 from the previous quarter.Despite Tuesday’s steep decline, sentiment on Stocktwits inched up to ‘bullish’ territory. Message volume climbed to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1306/312;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_12_at_10_25_15_AM_5a16851749.png" alt="Screenshot 2025-03-12 at 10.25.15 AM.png" width="1306" height="312"><figcaption>KSS sentiment meter and message volume on March 11 as of 11 pm ET</figcaption></figure>One bullish watcher was awaiting a recovery along with the market.<stembedurl>https://stocktwits.com/PenniesFromHell/message/607693772</stembedurl>Another watcher suggested the company should consider going private.<stembedurl>https://stocktwits.com/Millegan/message/607667972</stembedurl>Last month, Kohl’s said it has cut 10% of its corporate workforce to boost profitability. The news came shortly after the company also disclosed plans to close 27 of its “underperforming stores” in April.<a href="https://stocktwits.com/symbol/KSS">Kohl’s stock</a> is down 34% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kohl’s Stock Dives On Disappointing Outlook, But Retail’s Optimistic Post Q4 Results

Kohl’s posted better-than-expected earnings, with earnings per share of $0.95, surpassing estimates of $0.72.

FXD
First Trust Exchange-Traded Fund III - First Trust Consumer Discretionary AlphaDEX Fund

Feed

News

Sentiment

Fundamentals

Info

Latest FXD News

FXDFirst Trust Exchange-Traded Fund III - First Trust Consumer Discretionary AlphaDEX Fund